What is Evrys Bio?
Evrys Bio, founded on breakthrough discoveries from Princeton University, is pioneering a new approach to antiviral treatment. Unlike traditional immuno-oncology drugs that leverage the patient's immune system against cancer, Evrys Bio's antivirals are designed to activate the cell's intrinsic immunity to combat infections. The company's vision is to create first-in-class antivirals that offer safety, overcome acquired drug resistance, and provide broad-spectrum treatment options, aiming to holistically transform infectious disease management beyond targeting specific viruses.
How much funding has Evrys Bio raised?
Evrys Bio has raised a total of $3.4M across 1 funding round:
Private Equity
$3.4M
Private Equity (2016): $3.4M, investors not publicly disclosed
What's next for Evrys Bio?
The substantial enterprise-level funding Evrys Bio has attracted signals a critical growth phase, likely focused on advancing its pipeline through clinical trials and scaling its operational capabilities. This strategic investment will be instrumental in bringing its innovative antiviral solutions from discovery to market, potentially revolutionizing how infectious diseases are treated by offering a more robust and resistance-proof therapeutic strategy.
See full Evrys Bio company page
